Admedus announces new collaboration on stem cell therapy

Company News

Admedus (ASX:AHZ) announced it will work with the Ear Science Institute Australia (ESIA) using their regenerative cell biology expertise to facilitate the delivery of stem cells on ADAPT tissue in both in vitro and in vivo models.

The studies will investigate a range of bone marrow derived mesenchymal stem cells and adipose derived stem cells delivered on a variety of Admedus’ ADAPT treated tissues to examine their regenerative capacity.

“These are important studies to further validate the utility of ADAPT tissue as a delivery platform for stem cells and other cellular therapies,” said Admedus CEO, Mr Lee Rodne.

“The research using ADAPT tissue and stem cells is part of the Admedus strategy to develop a number of regenerative tissue products based on the ADAPT tissue engineering technology, which produces tissues that limit calcification and are effectively remodelled, making them ideal for a broader range of surgical products.”

The studies with ESIA will explore the levels of regeneration, vascularisation and cell differentiation when ADAPT tissue is used with stem cells.

Previous data in heart valves has shown a strong level of autologous regeneration and vascularisation around the ADAPT tissue that is facilitated by cells.

“We are excited to work with Admedus on this important project. As a leading research institution, there was a natural synergy between our work in studying regenerative cell biology and Admedus’ interest in using their bio-scaffolds to deliver stem cells. We look forward to continuing to work closely with Admedus in the aim of improving patient outcomes,” said Associate Professor Rodney Dilley, Head of Molecular and Cellular Otolaryngology at ESIA.

On identifying the most suitable stem cell population, Admedus will move into a separate larger scale in vivo study of tissue regeneration, including functional remodelling of the heart after myocardial infarct.